Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2008;39:185-190
Published online before print November 21, 2007, doi: 10.1161/STROKEAHA.107.487827
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/1/185    most recent
STROKEAHA.107.487827v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ansar, S.
Right arrow Articles by Edvinsson, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ansar, S.
Right arrow Articles by Edvinsson, L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage

(Stroke. 2008;39:185.)
© 2008 American Heart Association, Inc.


Original Contributions

Subtype Activation and Interaction of Protein Kinase C and Mitogen-Activated Protein Kinase Controlling Receptor Expression in Cerebral Arteries and Microvessels After Subarachnoid Hemorrhage

Saema Ansar, DMSci Lars Edvinsson, MD, PhD

From the Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Sweden; and the Department of Clinical Experimental Research, Glostrup University Hospital, Glostrup, Denmark.

Correspondence to Saema Ansar, Department of Clinical Sciences, Division of Experimental Vascular Research, BMC A13, Lund University, 221 84 Lund, Sweden. E-mail Saema.Ansar{at}med.lu.se

Background and Purpose— The pathogenesis of cerebral ischemia associated with subarachnoid hemorrhage (SAH) still remains elusive. The aim of this study was to examine the involvement of mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) subtypes in the pathophysiology of cerebral ischemia after SAH in cerebral arteries and microvessels and to examine temporal activation of the kinases. We hypothesize that treatment with a MAPK or PKC inhibitor will prevent the SAH-induced kinase activation in brain vessels.

Methods— SAH was induced by injecting 250 µL blood into the prechiasmatic cistern in the rat. The activation of different MAPK and PKC isotypes in large circle of Willis cerebral arteries and intracerebral microvessels was examined at 0, 1, 3, 6, 12, 24, and 48 hours after SAH and after intrathecal treatment with PKC or MAPK inhibitor by use of Western blot.

Results— Among the 8 investigated PKC isoforms, only PKC{delta} was activated at 1 hour and at 48 hours, whereas PKC{alpha} was activated at 48 hours after SAH. For the MAPKs, there was early phosphorylation at 1 hour of extracellular signal-regulated kinase 1/2, whereas c-jun N-terminal kinase and p38 showed enhanced phosphorylation only at 48 hours after SAH. The pattern was identical in large cerebral arteries and in intracerebral microvessels. Treatment with either the PKC (RO-31-7549) or the raf (SB386023-b) inhibitor prevented the kinase activation.

Conclusions— The results show that specific subtypes of the MAPK and PKC pathways are activated in cerebral arteries after SAH and the PKC and raf inhibitors are able to prevent this activation.


Key Words: cerebral arteries • cerebral ischemia • mitogen-activated protein kinase (MAPK) • protein kinase C (PKC) • subarachnoid hemorrhage (SAH)